FAST NEWS: Zai Lab Acquires Exclusive Greater China License for Cervical Cancer Drug
The latest: Biotech drug maker Zai Lab Ltd. (9688.HK; ZLAB.US) announced on Tuesday that one of its subsidiaries has obtained an exclusive license to develop and commercialize Seagen Inc.’s (SGEN.US) cervical cancer…
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
